Penglie Zhang

2.0k citations

37 papers · 1.2k indexed · h-index 18

Co-authors: Thomas J. Schall Juan C. Jaén Jay P. Powers Zhenhua MiaoYu WangMark E.T. Penfold Ali Jalili Robert Berahovich
Topics: Chemokine receptors and signaling (13 papers)Blood Coagulation and Thrombosis Mechanisms (10 papers)Receptor Mechanisms and Signaling (5 papers)
Cited by: Immunology Oncology Hematology
Journals: Nature Communications The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: United States Australia Denmark

In The Last Decade

Penglie Zhang

36 papers receiving 1.2k citations

Peers

Countries citing papers authored by Penglie Zhang

Since Specialization

Citations

This map shows the geographic impact of Penglie Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penglie Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penglie Zhang more than expected).

Fields of papers citing papers by Penglie Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penglie Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penglie Zhang. The network helps show where Penglie Zhang may publish in the future.

Co-authorship network of co-authors of Penglie Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Penglie Zhang. A scholar is included among the top collaborators of Penglie Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penglie Zhang. Penglie Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias 2022 ·Science Advances ·(unknown),(unknown),Martin Gustavsson,S.A. Eberle,Pawel K. Dominik,Dawid Deneka,Penglie Zhang,Thomas J. Schall,Anthony A. Kossiakoff,J.J.G. Tesmer,Tracy M. Handel	43
2	CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood 2019 ·The Journal of Immunology ·Bin Zhao,James J. Campbell,Catherina L. Salanga,Linda Ertl,Yu Wang,(unknown),(unknown),Yibin Zeng,(unknown),(unknown),Penglie Zhang,Irina Kufareva,Tracy M. Handel,Israel Charo,Rajinder Singh,Thomas J. Schall	19
3	CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS) 2018 ·PLoS ONE ·Zhenhua Miao,Linda Ertl,Dale Newland,Bin Zhao,Yu Wang,Xiaoping Zang,James J. Campbell,Xiaoli Liu,(unknown),Shichang Miao,(unknown),(unknown),Yibin Zeng,(unknown),Penglie Zhang,Israel Charo,Thomas J. Schall,Rajinder Singh	8
4	Structural basis of ligand interaction with atypical chemokine receptor 3 2017 ·Nature Communications ·Martin Gustavsson,Liwen Wang,Noortje van Gils,Bryan S. Stephens,Penglie Zhang,Thomas J. Schall,Sichun Yang,Ruben Abagyan,Mark R. Chance,Irina Kufareva,Tracy M. Handel	79
5	Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study 2016 ·PLoS ONE ·Pirow Bekker,Daniel J. Dairaghi,Lisa Seitz,Manmohan R. Leleti,Yu Wang,Linda Ertl,Trageen Baumgart,Sarah Shugarts,Lisa Lohr,(unknown),Shichang Miao,Yibin Zeng,Pingchen Fan,Penglie Zhang,Daniel E. Johnson,Jay P. Powers,Juan C. Jaén,Israel Charo,Thomas J. Schall	115
6	CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens 2013 ·Immunology Letters ·Matthew J. Walters,Karen Ebsworth,Timothy J. Sullivan,Penglie Zhang,Jay P. Powers,Juan C. Jaén,Thomas J. Schall	5
7	1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists 2013 ·Bioorganic & Medicinal Chemistry Letters ·Andrew M. K. Pennell,James B. Aggen,Subhabrata Sen,Wei Chen,(unknown),(unknown),Lianfa Li,Kevin L. Greenman,Trevor T. Charvat,(unknown),Daniel J. Dairaghi,John Joseph Wright,Penglie Zhang	11
8	Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands 2009 ·The Journal of Immunology ·Brian A. Zabel,Yu Wang,Susanna Lewén,Robert Berahovich,Mark E.T. Penfold,Penglie Zhang,Jay P. Powers,(unknown),Zhenhua Miao,Bin Zhao,Ali Jalili,Anna Janowska‐Wieczorek,Juan C. Jaén,Thomas J. Schall	245
9	Design, Synthesis and Discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as Highly Potent Factor Xa Inhibitors 2009 ·Chemical and Pharmaceutical Bulletin ·Zhaozhong J. Jia,Robert M. Scarborough,Penglie Zhang,(unknown),Ann Arfsten,Uma Sinha,Bing‐Yan Zhu	2
10	Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR 2009 ·Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang,Liang Bao,(unknown),Zhaozhong J. Jia,Uma Sinha,Paul Wong,Gary Park,Athiwat Hutchaleelaha,Robert M. Scarborough,Bing‐Yan Zhu	10
11	Inhibitory effect of carboxylic acid group on hERG binding 2006 ·Bioorganic & Medicinal Chemistry Letters ·Bing‐Yan Zhu,Zhaozhong J. Jia,Penglie Zhang,Ting Su,Wenrong Huang,Erick A. Goldman,Daniel B. Tumas,(unknown),(unknown),Uma Sinha,Robert M. Scarborough,Yonghong Song	39
12	Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo 2006 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey R. Spencer,Martin Sendzik,Jason Oeh,Peter Sabbatini,Stacie A. Dalrymple,Catherine Magill,Hyunjin M. Kim,Penglie Zhang,Neil Squires,Katherine G. Moss,Juthamas Sukbuntherng,(unknown),John Eksterowicz,Peter R. Young,Andrew G. Myers,Michael J. Green	15
13	N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Ting Su,(unknown),Yanhong Wu,Erick A. Goldman,Wenhao Li,Penglie Zhang,Lane A. Clizbe,Yonghong Song,(unknown),Wenrong Huang,John Woolfrey,Uma Sinha,Ann Arfsten,Athiwat Hutchaleelaha,Stanley J. Hollenbach,Joseph L. Lambing,Robert M. Scarborough,Bing‐Yan Zhu	12
14	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity 2004 ·Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang,Liang Bao,(unknown),Zhaozhong J. Jia,John Woolfrey,Ann Arfsten,Susan Edwards,Uma Sinha,Athiwat Hutchaleelaha,Joseph L. Lambing,Stanley J. Hollenbach,Robert M. Scarborough,Bing‐Yan Zhu	19
15	1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs 2004 ·Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Yanhong Wu,Wenrong Huang,Penglie Zhang,Lane A. Clizbe,Erick A. Goldman,Uma Sinha,Ann Arfsten,Susan Edwards,(unknown),Athiwat Hutchaleelaha,Robert M. Scarborough,Bing‐Yan Zhu	19
16	1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Yanhong Wu,Wenrong Huang,Penglie Zhang,Yonghong Song,John Woolfrey,Uma Sinha,Ann Arfsten,Susan Edwards,Athiwat Hutchaleelaha,(unknown),Joseph L. Lambing,Robert M. Scarborough,Bing‐Yan Zhu	43
17	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs 2004 ·Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang,Liang Bao,(unknown),Erick A. Goldman,Zhaozhong J. Jia,Ann Arfsten,Susan Edwards,Uma Sinha,Athiwat Hutchaleelaha,Gary Park,Joseph L. Lambing,Stanley J. Hollenbach,Robert M. Scarborough,Bing‐Yan Zhu	20
18	Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Wenrong Huang,Penglie Zhang,(unknown),Lingyan Wang,John Woolfrey,Yonghong Song,Zhaozhong J. Jia,Lane A. Clizbe,Ting Su,(unknown),Brian Huang,Paul Wong,Uma Sinha,Gary Park,(unknown),J Malinowski,Stanley J. Hollenbach,Robert M. Scarborough,Bing‐Yan Zhu	18
19	Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides 2002 ·Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Yanhong Wu,Wenrong Huang,Erick A. Goldman,Penglie Zhang,John Woolfrey,Paul Wong,Brian Huang,Uma Sinha,Gary Park,(unknown),Robert M. Scarborough,Bing‐Yan Zhu	16
20	Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors 2002 ·Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang,(unknown),John Woolfrey,(unknown),Brian Huang,Paul Wong,Uma Sinha,Gary Park,(unknown),J Malinowski,(unknown),Robert M. Scarborough,Bing‐Yan Zhu	10

About Penglie Zhang

Penglie Zhang is a scholar working on Hematology, Immunology and Oncology, having authored 37 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chemokine receptors and signaling (13 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Receptor Mechanisms and Signaling (5 papers). The work is most often cited by research in Immunology (586 citations), Oncology (583 citations) and Hematology (155 citations). Penglie Zhang has collaborated with scholars based in United States, Australia and Denmark. Frequent co-authors include Thomas J. Schall, Juan C. Jaén, Jay P. Powers, Zhenhua Miao, Yu Wang, Mark E.T. Penfold, Ali Jalili, Robert Berahovich, Bin Zhao and Susanna Lewén. Their work appears in journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact